PCI Biotech Holding ASA ( (DE:4QG) ) has shared an announcement.
PCI Biotech Holding ASA’s Board of Directors has approved the Annual Report for 2024, which is now accessible on the company’s website. This approval marks a significant step in the company’s compliance with regulatory requirements, potentially impacting its transparency and investor relations positively.
More about PCI Biotech Holding ASA
PCI Biotech Holding ASA operates in the biotechnology industry, focusing on the development of innovative cancer treatments. The company specializes in photochemical internalization technology, which enhances the efficacy of therapeutic molecules in cancer care.
YTD Price Performance: -2.00%
Average Trading Volume: 1,810
Technical Sentiment Signal: Buy
Current Market Cap: €4.07M
See more data about 4QG stock on TipRanks’ Stock Analysis page.